Ferrante Comments on CMS Proposal to Add Telehealth Coverage to Medicare Physician Fee Schedule
17 September 2018
Senior Counsel Thomas (T.J.) Ferrante was quoted in a Report on Medicare Compliance article, “Medical Center Provides Telehealth Follow-Up Visits With Eye on Future Medicare Coverage,” about a decision by the CMS to add telehealth coverage to the proposed 2019 Medicare Physician Fee Schedule (MPFS) regulation, including patient virtual check-ins with physicians.
Ferrante said that means that in some cases patients could be at home instead of at an “originating site” (e.g., hospital, physician practice), which is normally required to trigger Medicare payment for telehealth services. “It’s the most open I have seen CMS be to telemedicine,” he said. “Now that Medicare is starting to reimburse it, compliance and legal counsel will have to watch these programs.”
Ferrante said that means that in some cases patients could be at home instead of at an “originating site” (e.g., hospital, physician practice), which is normally required to trigger Medicare payment for telehealth services. “It’s the most open I have seen CMS be to telemedicine,” he said. “Now that Medicare is starting to reimburse it, compliance and legal counsel will have to watch these programs.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”